Histidine

Histidine

SCHEMBL4294462

NCCCC[C@H](N)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.54
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
ARG1 P05089 4/20 0.40
CPB2 Q96IY4 3/20 0.40
CPB1 P15086 1/20 0.40
CYP3A4 P08684 1/20 0.38
SLC7A5 Q01650 1/20 0.38
THRB P10828 1/20 0.38
CYP1A2 P05177 1/20 0.38
MMP2 P08253 1/20 0.37
ARG2 P78540 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL28245493 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
D-Histidine SCHEMBL902054 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL27440707 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL305856 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL305855 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL16714200 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL4297918 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL27767215 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL18419548 1.00 GSR (0.54) GSRITGB3ITGA2BARG1CPB2
Histidine SCHEMBL4735217 0.99 GSR (0.53) GSRITGB3ITGA2BARG1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3103446-A2 PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA Zakharov, Ivan Dmitrievich (RU) 2016-12-14 EP claimed
EP-3103446-B1 PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA ZAKHAROV IVAN DMITRIEVICH (RU) 2024-02-14 EP disclosed
EP-3103446-A2 PHARMACEUTICAL PREPARATION FOR PREVENTING AND TREATING PROGRESSIVE MYOPIA Zakharov, Ivan Dmitrievich (RU) 2016-12-14 EP disclosed
US-20130123330-A1 Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases LU PATRICK Y (US) 2013-05-16 US disclosed
US-20090247604-A1 RNAi Therapeutics for Treatment of Eye Neovascularization Diseases INTRADIGM CORPORATION (US) 2009-10-01 US disclosed
WO-2008154482-A2 SIRNA COMPOSITIONS AND METHODS OF USE IN TREATMENT OF OCULAR DISEASES SIRNAOMICS, INC. (US) 2008-12-18 WO disclosed
CN-101199858-A Multiple target point small interference RNA cocktail agent for treating ophthalmic disease and preparing method thereof GUANGZHOU TOP GENOMICS LTD (CN) 2008-06-18 CN disclosed
EP-1711510-A2 RNAI THERAPEUTICS FOR TREATMENT OF EYE NEOVASCULARIZATION DISEASES Intradigm Corporation (US) 2006-10-18 EP disclosed
WO-2005076998-A2 RNAI THERAPEUTICS FOR TREATMENT OF EYE NEOVASCULARIZATION DISEASES INTRADIGM CORPORATION (US) 2005-08-25 WO disclosed